AEROVATE THERAPEUTICS INC's ticker is AVTE and the CUSIP is 008064107. A total of 47 filers reported holding AEROVATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,390,370 | -2.6% | 249,808 | +23.0% | 0.00% | – |
| Q2 2023 | $3,482,444 | -7.9% | 203,058 | +8.3% | 0.00% | – |
| Q1 2023 | $3,781,854 | +72183.1% | 187,499 | +5.0% | 0.00% | -100.0% |
| Q4 2022 | $5,232 | -99.8% | 178,596 | +5.3% | 0.00% | – |
| Q3 2022 | $2,811,000 | +8.2% | 169,599 | +2.1% | 0.00% | – |
| Q2 2022 | $2,597,000 | -27.4% | 166,162 | -14.9% | 0.00% | – |
| Q1 2022 | $3,577,000 | +92.4% | 195,187 | +23.7% | 0.00% | – |
| Q4 2021 | $1,859,000 | -22.5% | 157,730 | +37.8% | 0.00% | – |
| Q3 2021 | $2,400,000 | – | 114,423 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| OUP Management Co., LLC | 603,762 | $8,193,050 | 18.42% |
| TCG Crossover Management, LLC | 2,201,274 | $29,871,288 | 4.40% |
| Atlas Venture Life Science Advisors, LLC | 2,039,249 | $27,672,609 | 4.29% |
| Sofinnova Investments, Inc. | 3,758,686 | $51,005,369 | 3.22% |
| GREAT POINT PARTNERS LLC | 1,091,233 | $14,808,032 | 2.70% |
| RA Capital Management | 8,263,982 | $112,142,236 | 2.21% |
| Cormorant Asset Management, LP | 1,561,696 | $21,192,215 | 1.24% |
| Frazier Life Sciences Management, L.P. | 1,204,867 | $16,350,045 | 1.09% |
| Octagon Capital Advisors LP | 497,370 | $6,749,311 | 1.04% |
| Ghost Tree Capital, LLC | 201,197 | $2,730,243 | 0.90% |